Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders

HONG KONG, Oct 30, 2025 – (ACN Newswire)– Everest Medicines (HKEX:1952. HK) today revealed that it has actually obtained a special license with Visara, Inc. (“Visara”), a subsidiary of NovaBridge Biosciences (officially referred to as I-Mab, and is a business noted on the Nasdaq Global Market trading under the sign “NBP”), to protect an unique license to establish, produce and advertise VIS-101, in Greater China, Singapore, South Korea and specific Southeast Asian nations.

This partnership marks Everest’s tactical growth into ophthalmology, a high-potential “blue-ocean” healing location, additional enhancing its late-stage item pipeline and reinforcing synergies throughout its core restorative portfolio.

Under the appointed special license, Everest Medicines will make an in advance payment of US$ 7 million (equivalent to around RMB49.7 million) and compensate as much as RMB24.0 million for previous expenditures; and pay up to US$ 89.0 million (equivalent to roughly RMB632.0 million) in prospective turning points; plus connected royalties on net sales.

“We are delighted to work together with Visara. This collaboration brings an extremely distinguished and commercially appealing property to Everest’s late-stage item pipeline and marks our entry into ophthalmology, a competitively appealing healing location with substantial unmet medical requirements,” stated Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “Leveraging Everest’s scientific advancement and commercialization knowledge, we anticipate advancing VIS-101, a prospective best-in-class bifunctional antibody, towards commercialization in China and throughout Asia.”

VIS-101 is an unique bifunctional biologic targeting VEGF-A and ANG-2 that is more powerful and might possibly offer more long lasting treatment advantages than existing treatments for clients with damp age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. VIS-101 has actually finished preliminary security and dose-escalation research studies in both the United State of America and China, and is presently finishing a randomized, dose-ranging Phase 2 research study in China. VIS-101 is expected to be Phase 3-ready in 2026.

“VIS-101 is expected to be second-in-class with best-in-class capacity, based upon bioengineered, exceptional target reducing the effects of abilities.” stated Dr. Emmett T. Cunningham, Jr, Co-Founder and Executive Chairman of Visara.

Worldwide, the marketplace size for anti-VEGF ophthalmic drugs reached roughly USD 23 billion in 2024 and is predicted to surpass USD 40 billion by 2030. In China alone, the widespread client population of AMD and DME goes beyond 15 million, with around 600,000 brand-new cases each year, yet just about 500,000 clients presently get treatment. This shows large market capacity.

Visara is a subsidiary of NovaBridge Biosciences (Nasdaq: NBP), of which Everest Medicines is presently the biggest investor. “Licensing out Greater China, South Korea and Southeast Asia rights to Everest Medicines is a crucial action towards simplifying international industrial rights and producing synergy in international medical advancement,” stated Dr. Sean Fu, Chief Executive Officer of NovaBridge Biosciences. “We are delighted to deal with Everest Medicines group as a tactical partner.”

Under its “dual-engine” method, Everest Medicines has actually developed a commercialization platform anchored by 2 smash hit items targeting high-potential markets and powered by the in-house in vivo CAR-T and mRNA restorative cancer vaccine platforms. The Company will continue to concentrate on essential healing locations and brand-new development markets, with ophthalmology as the next development chauffeur to reinforce synergy throughout its core portfolio.

Everest’s core item pipeline in rental illness, transmittable illness, and autoimmune conditions has actually gotten in a crucial development phase. NEFECON ® and XERAVA ® have actually developed sustainable industrial capital generation, while VELSIPITY ®(etrasimod) is anticipated to end up being the business’s next smash hit item. Everest continues to boost its development ability and long-lasting competitiveness by leveraging its industry-leading mRNA restorative cancer vaccine platform and mRNA in vivo CAR-T platform.

At a current business method conference, Everest Medicines revealed strategies to in-license more than 3 high-potential possessions within the next 6– 12 months, with an aggregate domestic peak sales prospective surpassing RMB10 billion. Integrated with its existing portfolio, Everest Medicines anticipates its overall domestic peak sales capacity to exceed RMB20 billion.

Subject: Press release summary